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eﬂections  on  the  role of  the  vaccine  against
uman papillomavirus  (HPV)  in Sexually
ransmitted Diseases  (STDs)
ear Editor,
exually Transmitted Diseases (STDs) cause serious dam-
ge; among other, gynecological and anal cancers, in that
PV is the carcinogen in 90% of cases. The prevention of
hese diseases is based on people’s education, but their treat-
ent and vaccination occupy an increasingly greater space. In
his context, are particularly important (www.aids.gov.br and
ww.dst.uff.br):
. Hygiene, particularly peri-intercourse hygiene;
. Responsibility with respect to one’s partners, for instance,
the correct use of condoms and care with extramarital sex;
. A correct and early treatment of STDs and the partner’s
protection during this period;
. General preventive care, such as a regular gynecological
review;
. Access to diagnosis, treatment and information about
STDs, and
. Vaccination, currently available for some STDs, such as
HPV.
Concerning HPV vaccination, ANVISA currently recom-
ends the tetravalent vaccine for men  and women aged 9–26
ears; and the bivalent vaccine for women over 9 years old
www.anvisa.gov.br). On the other hand, some studies discuss
he beneﬁts of expanding the indication for other age groups,
nd also for people already infected with HPV. There is even a
roject of law moving through Brazilian Congress (PLS 238/11)
andating the vaccination for women between 9 and 40 years.
he extent of this beneﬁt for a larger number of Brazilian peo-
le also depends on public awareness, costs, side effects and
eneﬁts of the vaccine.
The awareness of the population depends on informative
ampaigns to clarify about STDs, especially the beneﬁts of HPV
accination, vaccine indications and location of vaccination
osts. The vaccine costs will decrease with the development
f a national technology aiming to a large-scale vaccine pro-duction. The vaccine has minor side effects, compared to its
beneﬁts, and these side effects should decrease with vaccine
improvement.1–6
Some facts emphasize the beneﬁts of the vaccine, leading
to reﬂections on the possibility of expanding its indications
for other age groups and for people already infected with HPV,
such as:
1. HPV vaccines cover part of viral types. In an individual,
the infection can occur by types different from those that
constitute the viral vaccine, in which case the vaccinated
individual would be protected, if a new infection caused by
any of HPV types targeted by the vaccine occurs.7 In addi-
tion, some studies suggest that the vaccine can improve
immunity against viral types not present in the vac-
cine, inﬂuencing the treatment and the resistance against
disease.8–11
2. STDs are entry points for other STDs or for different viral
types of the same STD. When the body’s immunity is
improved with the vaccine and when infections by those
HPV types present in the vaccine are prevented, we  are
improving the protection of the body from being infected
by new STDs, or by other viral types.9
3. There is a better chance that a STD-infected individual
do not follow those preventive care measures above men-
tioned, therefore being at greater risk of recontamination.
In this case, the vaccine protects against diseases caused by
those HPV types that make up the vaccine, notwithstand-
ing this behavior.
In conclusion, we believe that demonstrating the advan-
tages of expanding the indication of ANVISA towards
vaccinating people of other age groups and also those who
have had HPV disease, together with an appropriate invest-
ment in research, production and distribution of the vaccine
by the Ministry of Health, cancer mortality, absence from
work, poor quality of life and the cost of Health will be
diminished.12–14
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